Trial · NCT02820324

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

NCT02820324, Phase 3, Completed, Trevena Inc.; results first posted 2020-10-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty. Trials, record NCT02820324. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02820324

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
NCT number: NCT02820324
Status: Completed
Phases: Phase 3
Enrollment: 407 participants, actual
Lead sponsor: Trevena Inc.
Conditions: Acute Pain
Interventions: Oliceridine, Placebo, Morphine
First posted: 2016-06-30
Last updated: 2020-10-23
Results first posted: 2020-10-23

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.	24 hours	The NPRS is an 11-point scale from 0-10 where "0" = no pain and "10" = the most intense pain imaginable. A patient was a responder if: their final time-weighted Sum of Pain Intensity Difference (SPID)-24 corresponded to a ≥30% improvement without rescue pain medication during the Randomized Treatment Period, without early discontinuation of study medication for any reason, and without reaching the study medication dosing limit.
Secondary	Number of Respiratory Safety Events Compared to Morphine.	24 hours	Respiratory Safety Events were defined as a clinically relevant worsening of respiratory status.
Secondary	Duration of Respiratory Events Compared to Morphine.	24 hours	Respiratory Safety Events were defined as a clinically relevant worsening of respiratory status.
Secondary	Odds Ratio of Patients Who Respond to Study Medication at the 24-hr NPRS Assessment Compared to Morphine.	24 hours	Odds ratio of 24-hour responder analysis versus morphine. Number of patients who responded to study medication at the 24-hr NPRS assessment is captured in the primary outcome measure.
Secondary	Number of Patients With Treatment-related Adverse Events Compared to Placebo and Compared to Morphine.	24 hours

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.	24 hours	The analysis population reflects the number of patients treated with study medication.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Respiratory Safety Events Compared to Morphine.	24 hours	The analysis population reflects the number of patients treated with study medication.	Respiratory Safety Events	NUMBER
SECONDARY	Duration of Respiratory Events Compared to Morphine.	24 hours	The analysis population reflects the number of patients treated with study medication.	hours	MEAN
SECONDARY	Odds Ratio of Patients Who Respond to Study Medication at the 24-hr NPRS Assessment Compared to Morphine.	24 hours	The analysis population reflects the number of patients treated with study medication. The morphine and placebo Arms/Groups are not included, as this is a comparison of study medication against morphine.	odds ratio	NUMBER
SECONDARY	Number of Patients With Treatment-related Adverse Events Compared to Placebo and Compared to Morphine.	24 hours		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group23

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.	Treatment 1 Oliceridine	47	Participants
Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.	Treatment 2 Oliceridine	61	Participants
Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.	Treatment 3 Oliceridine	56	Participants
Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.	Treatment 4 Placebo	37	Participants
Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.	Treatment 5 Morphine	65	Participants
Number of Respiratory Safety Events Compared to Morphine.	Treatment 1 Oliceridine	6	Respiratory Safety Events
Number of Respiratory Safety Events Compared to Morphine.	Treatment 2 Oliceridine	17	Respiratory Safety Events
Number of Respiratory Safety Events Compared to Morphine.	Treatment 3 Oliceridine	18	Respiratory Safety Events
Number of Respiratory Safety Events Compared to Morphine.	Treatment 4 Placebo	5	Respiratory Safety Events
Number of Respiratory Safety Events Compared to Morphine.	Treatment 5 Morphine	22	Respiratory Safety Events

1 to 10 of 23Source ClinicalTrials.gov

See all 23 results by group

Participant flow20

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment 1 Oliceridine	78
Overall Study	STARTED	Treatment 2 Oliceridine	82
Overall Study	STARTED	Treatment 3 Oliceridine	82
Overall Study	STARTED	Treatment 4 Placebo	82
Overall Study	STARTED	Treatment 5 Morphine	83
Overall Study	Treated With Study Medication	Treatment 1 Oliceridine	77
Overall Study	Treated With Study Medication	Treatment 2 Oliceridine	80
Overall Study	Treated With Study Medication	Treatment 3 Oliceridine	80
Overall Study	Treated With Study Medication	Treatment 4 Placebo	81
Overall Study	Treated With Study Medication	Treatment 5 Morphine	83

1 to 10 of 20Source ClinicalTrials.gov

See all 20 participant flow

Adverse events130

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nausea	Gastrointestinal disorders	Treatment 1 Oliceridine	34	77
other	Nausea	Gastrointestinal disorders	Treatment 2 Oliceridine	49	80
other	Nausea	Gastrointestinal disorders	Treatment 3 Oliceridine	60	80
other	Nausea	Gastrointestinal disorders	Treatment 4 Placebo	38	81
other	Nausea	Gastrointestinal disorders	Treatment 5 Morphine	61	83
other	Vomiting	Gastrointestinal disorders	Treatment 1 Oliceridine	18	77
other	Vomiting	Gastrointestinal disorders	Treatment 2 Oliceridine	17	80
other	Vomiting	Gastrointestinal disorders	Treatment 3 Oliceridine	34	80
other	Vomiting	Gastrointestinal disorders	Treatment 4 Placebo	11	81
other	Vomiting	Gastrointestinal disorders	Treatment 5 Morphine	44	83

1 to 10 of 130Source ClinicalTrials.gov

See all 130 adverse events

Adverse event totals15

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treatment 1 Oliceridine	0	77
Total, all-cause mortality	Treatment 2 Oliceridine	0	80
Total, all-cause mortality	Treatment 3 Oliceridine	0	80
Total, all-cause mortality	Treatment 4 Placebo	0	81
Total, all-cause mortality	Treatment 5 Morphine	0	83
Total, other adverse events	Treatment 1 Oliceridine	69	77
Total, other adverse events	Treatment 2 Oliceridine	74	80
Total, other adverse events	Treatment 3 Oliceridine	76	80
Total, other adverse events	Treatment 4 Placebo	65	81
Total, other adverse events	Treatment 5 Morphine	80	83

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
31162798	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02820324

GET https://conductscience.org/api/trials/v1/NCT02820324/results?page=2

API reference For AI assistants